The Sevillian startup Duponte, which operates in the pharmacogenomics sector, has launched an artificial intelligence tool called Matchgenicwhich allows determining the response of patients to a certain treatment, based on their genomics.
“Currently, the only way to ensure effective treatment without incurring trial and error is DNA sequence analysis, which is not widely used because it is expensive for health institutions”, indicates Yolima Puentes, CEO of Duponte. In a first stage, the company wants to offer this tool for pharmacogenomic analysis to health centers with patients undergoing treatment for cancer.
“With this artificial intelligence tool it will be possible to determine how they will respond or not to each type of medication, which will help to prescribe them appropriately”, says the entrepreneur.
According to a study by the oncology division of The Washington University, the cases of pharmacological non-response that have occurred in anticancer treatment have increased by 75%, which makes clear the need for a diagnosis prior to the implementation of a treatment. medicine. For this reason, a tool like Matchgénica can be key to starting preventive and adequate treatments in the control of diseases such as cancer.
This company, supported by the Minerva Program of the Ministry of Economic Transformation, Industry, Knowledge and Universities and Vodafone, will enable health institutions to anticipate the effectiveness of the treatments they prescribe to their patients. Health institutions that want to participate in the project can register on the page website www.duponteadn.com until July 31 of this year. Up to 16 hospitals in the province of Seville could benefit from this prevention project.
